The University of Kansas Cancer Center requests CCSG funds for developmental funds to be specifically used for the pilot studies program and to supplement new recruitment packages. The major purpose of the Pilot Studies Program is to provide support for highly innovative research proposals in new, exciting, and potentially breakthrough areas of cancer research. The pilot research proposal must be cancer-related and must not overlap with existing funding from any source (different focus and different aims). Ultimately, the goal is to have these funds provide critical preliminary data to test new hypotheses and assess feasibility of ideas that might allow for rapid advancement in the field and make an impact in basic, clinical, or translational research. The merit of these proposals will be assessed by members of the KUCC-Leadership Council and approved by the Director prior to funding. To actively build and improve our research environment, KUCC is committed to recruiting additional cancer researchers to increase the national and international status of the Cancer Center, enhance the number of NCI/cancer-related grants, fill critical research positions and build the four cancer research programs. Each purposeful hire aims to further the scientific vision, mission, and goals of the Cancer Center research programs. The funds requested will be used to supplement the recruitment packages of future cancer center recruits and will be leveraged by matching with Kansas Bioscience Authority funds.

Public Health Relevance

The University of Kansas Cancer Center plans to utilize developmental funds to continue and to supplement its highly successful pilot project program to provide funding to test new research ideas. In addition, we will use a portion of the funds to supplement recruitment packages for new investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA168524-02
Application #
8557677
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
2
Fiscal Year
2013
Total Cost
$171,960
Indirect Cost
Name
University of Kansas
Department
Type
DUNS #
016060860
City
Kansas City
State
KS
Country
United States
Zip Code
66160
Kumar, Dhruv; New, Jacob; Vishwakarma, Vikalp et al. (2018) Cancer-Associated Fibroblasts Drive Glycolysis in a Targetable Signaling Loop Implicated in Head and Neck Squamous Cell Carcinoma Progression. Cancer Res 78:3769-3782
Vishwakarma, Vikalp; New, Jacob; Kumar, Dhruv et al. (2018) Potent Antitumor Effects of a Combination of Three Nutraceutical Compounds. Sci Rep 8:12163
Sharma, Priyanka; López-Tarruella, Sara; García-Saenz, José Angel et al. (2018) Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clin Cancer Res 24:5820-5829
Snyder, Vusala; Reed-Newman, Tamika C; Arnold, Levi et al. (2018) Cancer Stem Cell Metabolism and Potential Therapeutic Targets. Front Oncol 8:203
Chen, Yvonnes; Fowler, Carina H; Papa, Vlad B et al. (2018) Adolescents' behavioral and neural responses to e-cigarette advertising. Addict Biol 23:761-771
Mudaranthakam, Dinesh Pal; Thompson, Jeffrey; Hu, Jinxiang et al. (2018) A Curated Cancer Clinical Outcomes Database (C3OD) for accelerating patient recruitment in cancer clinical trials. JAMIA Open 1:166-171
Ranjan, Atul; Iyer, Swathi V; Ward, Christopher et al. (2018) MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma. Oncotarget 9:21429-21443
Brody, Jonathan R; Dixon, Dan A (2018) Complex HuR function in pancreatic cancer cells. Wiley Interdiscip Rev RNA 9:e1469
Sharma, P; Barlow, W E; Godwin, A K et al. (2018) Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313). Ann Oncol 29:654-660
Campos, Camila D M; Gamage, Sachindra S T; Jackson, Joshua M et al. (2018) Microfluidic-based solid phase extraction of cell free DNA. Lab Chip 18:3459-3470

Showing the most recent 10 out of 177 publications